l e t t e r s
Genome-wide association studies (GWAS) of chronic lymphocytic leukemia (CLL) have shown that common genetic variation contributes to the heritable risk of CLL. To identify additional CLL susceptibility loci, we conducted a GWAS and performed a meta-analysis with a published GWAS totaling 1,739 individuals with CLL (cases) and 5,199 controls with validation in an additional 1,144 cases and 3,151 controls. A combined analysis identified new susceptibility loci mapping to 3q26.2 (rs10936599, P = 1.74 × 10 −9 ), 4q26 (rs6858698, P = 3.07 × 10 −9 ), 6q25.2 (IPCEF1, rs2236256, P = 1.50 × 10 −10 ) and 7q31.33 (POT1, rs17246404, P = 3.40 × 10 −8 ). Additionally, we identified a promising association at 5p15.33 (CLPTM1L, rs31490, P = 1.72 × 10 −7 ) and validated recently reported putative associations at 5p15.33 (TERT, rs10069690, P = 1.12 × 10 −10 ) and 8q22.3 (rs2511714, P = 2.90 × 10 −9 ). These findings provide further insights into the genetic and biological basis of inherited genetic susceptibility to CLL.
CLL is the most common hematological malignancy in western countries 1 and is characterized by an eightfold increased risk in first-degree relatives 2 . GWAS have so far identified common variants at 24 loci that contribute to the heritable risk of CLL [3] [4] [5] [6] . Current projections for the number of independent regions harboring common variants that are associated with CLL suggest that additional risk loci conferring modest effects should be identified by the expansion of discovery GWAS data sets.
To identify additional susceptibility loci for CLL, we conducted an independent primary scan of CLL and performed a genome-wide meta-analysis with a previously published GWAS followed by analysis of the top SNPs in two separate case-control series.
In the primary scan (UK-CLL-2), we genotyped 1,271 cases using the Illumina Omni Express BeadChip. The newly scanned cases comprised 1,111 cases collected through the Institute of Cancer Research and Royal Marsden National Health Service Hospitals Trust and 160 cases from the Newcastle CLL Consortium (NCLLC). For controls, we used publicly accessible Hap1.2M-Duo Custom array data generated on 2,501 individuals from the UK Blood Service Control Group.
Our previous GWAS of CLL (UK-CLL-1) was based on a scan of 517 cases (155 of which were potentially enriched for genetic susceptibility by virtue of family history) using Illumina HumanCNV370-Duo BeadChips 3 . For controls, we used Hap1.2M-Duo Custom array data generated on 2,698 individuals from the Wellcome Trust Case Control Consortium 2 (WTCCC2) 1958 Birth cohort (also known as the National Child Development Study).
Quantile-quantile plots of the genome-wide P values showed that there was minimal inflation of the test statistics, rendering substantial cryptic population substructure or differential genotype calling between cases and controls unlikely in each of the GWAS (genomic control inflation factors (λ) of 1.04 and 1.05, respectively; Supplementary Fig. 1 ). To harmonize the two GWAS data sets, we imputed UK-CLL-1 to recover untyped SNPs that were directly genotyped in UK-CLL-2 using data from the 1000 Genomes Project as a reference. Using data on all cases and controls from each GWAS, we derived joint odds ratios (ORs) and confidence intervals (CIs) under a fixed-effects model for each SNP, as well as the associated P values, and restricted our analysis to SNPs with minor allele frequency A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia l e t t e r s (MAF) >1%. After filtering on the basis of prespecified quality-control measures (Online Methods), the two studies provided genotype data on 450,000 autosomal SNPs for 1,739 cases and 5,199 controls ( Supplementary Fig. 2 ). In the meta-analysis, associations for all 22 established loci (24 variants) showed a consistent direction of effect with previously reported studies, with 9 loci having P < 5.0 × 10 −8 ( Supplementary Fig. 3 and Supplementary Table 1) .
In the combined analysis, we identified two SNPs (rs2236256 and rs6062501) showing genome-wide significant evidence of association (P ≤ 5.0 × 10 −8 ) and mapping to distinct loci that have not previously been associated with CLL risk (Supplementary Table 2 ). We also identified promising association signals (P < 1.0 × 10 −5 ) at 11 additional loci (Supplementary Table 2 ). We applied 1000 Genomes imputation to UK-CLL-1 and UK-CLL-2 at these loci to investigate whether a statistically significant stronger SNP association could be identified, which recovered an additional SNP that was significant at the genome-wide threshold (rs6858698; Supplementary Table 2) . We performed replication genotyping of six SNPs selected on the basis of either statistical significance (rs2236256, rs6062501 and rs6858698) or gene centricity coupled with considerations of potential candidacy (i.e., a role in B-cell or cancer biology; rs10936599, rs31490 and rs17246404) in case-control series from the UK (803 cases and 2,780 controls) and Sweden (341 cases and 371 controls) (Online Methods, Supplementary Fig. 2 and Supplementary Table 3) . In a meta-analysis of all four data sets, four SNPs showed evidence for an association with CLL risk that was genome-wide significant ( Fig. 1  and Supplementary Table 3) .
The strongest evidence of association was attained with rs2236256 at 6q25.2 (OR = 1.23, 95% CI 1.15-1.30, P = 1.50 × 10 −10 , P het = 0.21, I 2 = 34%; Fig. 1 and Supplementary Table 3 ). This SNP localizes to the 3′ UTR of the interaction protein for IPCEF1, the cytohesin exchange factors 1 gene (Fig. 2) . IPCEF1 encodes the C-terminal half of CNK3, which is one of the CNK scaffolds that is involved in signal transduction downstream of Ras. To explore the epigenetic profile of the 6q25.2 association signal, we used chromatin state segmentation based on lymphoblastoid cell line (LCL) data from the Encyclopedia of DNA Elements (ENCODE) project 7 . rs2236256 is predicted to reside within a strong enhancer element, which raises the possibility of functionality per se ( Fig. 2 and Supplementary Table 4) .
We observed the second strongest signal for rs10936599 at 3q26.2 (OR = 1.26, 95% CI 1.17-1.35, P = 1.74 × 10 −9 , P het = 0.99, I 2 = 0%; Fig. 1 and Supplementary Table 3) , which corresponds to a p.His717His polymorphism in MYNN, the myoneurin gene (MIM606042). Carrier status for the rs10936599[C] allele has been shown previously to influence the risk of both colorectal cancer and multiple myeloma 8, 9 . Whereas MYNN encodes a zinc finger protein of unknown function that is expressed principally in muscle, rs10936599 (169,492,101 bp) maps within a 250-kb region of linkage disequilibrium (LD) that also encompasses TERC, the telomerase RNA component gene (MIM602322; Fig. 2 ). The imputed SNP rs2293607, which is correlated with rs10936599 (r 2 = 1.0, D′ = 1.0) and maps 63 bp 5′ to TERC, was recently shown to be associated with TERC mRNA expression in a colorectal cancer cell line 10 . rs2293607 is predicted to lie within an active promoter region ( Fig. 2) and is a transcription factor binding site for multiple proteins, including OCT2 (also called POU2F2), ELF1, NFKB and CMYC, which are important in the regulation of B-cell gene expression (Supplementary Table 4 ). Although we found no evidence for a relationship between rs10936599 and telomere length in 246 patients with CLL (Supplementary Table 5) , carrier status for the rs10936599[C] risk allele has previously been associated with significantly longer telomeres in leukocytes 10, 11 .
The third significant association was with rs6858698 at 4q26 (OR = 1.31, 95% CI 1.20-1.44, P = 3.07 × 10 −9 , P het = 0.18, I 2 = 39%; Fig. 1 and Supplementary Table 3) , which maps 760 bp upstream of CAMK2D, the calcium/calmodulin-dependent protein kinase II-δ gene (MIM607708, Fig. 2 ). Although CAMK2D does not currently have a documented role in CLL, calcium/calmodulin signaling has a role in the regulation of gene expression after B-cell activation through inhibition of transcription factor E2A 12 . Because rs6858698 resides within a conserved region (Genomic Evolutionary Rate Profiling (GERP) score of 2.40) and maps to a predicted promoter with binding sites for multiple transcription factors, it is possible that this SNP is responsible for the 4q26 association ( Fig. 2 and  Supplementary Table 4) .
The fourth significant SNP association was shown by rs17246404 at 7q31.33 (OR = 1.22, 95% CI 1.14-1.31, P = 3.40 × 10 −8 , P het = 0.77, I 2 = 0%; Fig. 1 and Supplementary Table 3) , which maps to the 3′ UTR of POT1, the protection of telomeres 1 gene (MIM606478; Fig. 2 Observed -log npg l e t t e r s POT1 forms part of the shelterin complex that functions to protect telomeres and maintain chromosomal stability. Recently, sequence analysis demonstrated somatic mutations of POT1 in 3.5% of all CLL and 9% of IGHV (encoding immunoglobulin heavy chain variable)-unmutated CLL 13 . Because POT1-mutated cells have numerous telomeric and chromosomal abnormalities, it has been suggested that POT1 mutation facilitates the acquisition of the malignant features of CLL cells. Telomeric deprotection has been postulated to be an early step in the evolution of CLL, not merely as a consequence of telomere shortening but also of shelterin alteration. Hence, it is plausible that the functional basis of the 7q31.33 association is through aberrant POT1 expression. In addition to these four risk loci, we identified a promising association at 5p15.33 defined by rs31490 (OR = 1.18, 95% CI 1.11-1.26, P = 1.72 × 10 −7 ; Fig. 1 and Supplementary Table 3) , which resides within intron 2 of CLPTM1L, the cleft lip and palate transmembrane protein 1-like gene (also called CRR9 or the cisplatin resistancerelated protein 9 gene; MIM612585; Fig. 2 ), which encodes a transcript whose overexpression has been linked to cis-platinum resistance by enhancing apoptosis. A recent GWAS of CLL 6 reported promising associations at 5p15.33 defined by rs10069690 and at 8q22.33 defined by rs2511714. Combining the P values for rs10069690 and rs2511714 obtained in our meta-analysis (P = 1.0 × 10 −4 and 1.0 × 10 −3 , respectively) with published data 6 provides robust evidence for both associations (combined P = 1.10 × 10 −10 and 2.90 × 10 −9 , respectively; Supplementary Fig. 4 ). rs10069690 maps to intron 4 of TERT (encoding telomerase reverse transcriptase; MIM187270) at 5p15.33 and is independent of the rs31490 association. rs2511714 maps 5.6 kb telomeric to ODF1, the gene encoding outer dense fiber of sperm tails 1 (MIM182878), within an ~10-kb region of LD.
CLL cells are characterized by short telomeres despite a low proliferative index; hence, both CLPTM1L and TERT at 5p15.33 are attractive candidates for CLL susceptibility a priori, assuming that the causal variant exerts an influence through a cis effect. Notably, the 5p15.33 TERT-CLPTM1L region is characterized by multiple distinct risk loci with different tumor specificities. rs31490 is highly correlated with rs401681, which also maps within intron 2 of CLPTM1L (r 2 = 0.93, D′ = 0.98). The T allele of rs401681 that increases CLL risk also increases the risk of pancreatic cancer 14 and melanoma 15, 16 but is associated with reduced risk of lung 17 and bladder cancer 18 . Carrier status for the CLL risk allele rs10069690 [T] has been shown previously to increase breast and ovarian cancer 19, 20 risk but reduce the risk of testicular cancer 21 .
CLL is characterized by male predominance and can be classified on the basis of the presence or absence of somatic hypermutations of the IGHV genes, with IGHV-mutated CLL typically having a more benign prognosis 22 . None of the seven SNPs (rs10936599, rs6858698, rs2236256, rs17246404, rs31490, rs10069690 and rs2511714) showed a significant relationship with these traits after adjustment for multiple testing (Supplementary Table 5 ). Although none of the seven SNPs or previously identified risk SNPs showed a relationship with age at diagnosis individually, cases diagnosed at a young age tended to carry a higher number of risk alleles (P = 0.01), which is consistent with early onset CLL being enriched for genetic susceptibility.
To gain understanding of the functional basis of the new CLL loci, we examined publically available expression quantitative trait loci data obtained from the analysis of LCLs 23 . Only one of the seven SNPs, rs10936599, was associated (P < 0.05) with transcript levels of a gene in cis (Supplementary Table 6) . Irrespective of the functional basis of the associations we identified, the potential impact of common alleles on gene expression will be modest and could occur at any time before diagnosis of CLL. Moreover, expression differences may be relevant only to a subpopulation of cells that provide 'targets' for leukemogenic mutations.
To gain insight into the allelic architecture of predisposition to CLL, we looked for interactive effects between 3q26.2, 4q26, 5p15.33, 6q25.2 and 7q31.33 and the previously identified CLL risk SNPs (Supplementary Table 7 ). There was no evidence of significant interaction (P > 0.05 after adjustment for multiple testing), which is compatible with each locus having an independent effect on CLL risk.
Our GWAS of CLL identified four new loci and validated two recently identified promising associations, bringing the total number of common risk variants for CLL to 30. Although additional studies will be required to decipher the functional basis of these risk loci, the proximity of several of the loci to genes having a role at telomeres suggests a plausible mechanism of biological relevance.
The contribution of all common variation to the heritability of CLL is around 46-59% (refs. 6,24). Collectively, the 30 risk variants identified thus far show an area under the curve of 0.74 and account for 19% of the familial risk of CLL. It is therefore likely that a substantial number of additional common variants remain to be discovered by further GWAS-based initiatives. Although the power of our study to detect common loci conferring risks of ≥1.3 was high, we had low power to detect alleles with smaller effects and/or MAF <0.1. By implication, variants with such profiles are likely to represent a much larger class of susceptibility loci for CLL because of truly small effect sizes or submaximal LD with tagging SNPs. Further efforts to expand the scale of GWAS, in terms of both sample size and SNP coverage, and increase the number of SNPs taken forward to large-scale replication should therefore identify additiYonal risk variants for CLL. 
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Ethics. Collection of samples and clinicopathological information from subjects was undertaken with informed consent and relevant ethical review board approval in accordance with the tenets of the Declaration of Helsinki.
Subjects. For both incident and prevalent cases, the diagnosis of CLL has been confirmed in accordance with World Health Organization classification guidelines 25 .
GWAS data sets. UK-CLL-2 comprised 1,271 cases collected from two ongoing initiatives: (i) 1,111 cases collected through a UK national study of CLL genetics coordinated by the Institute of Cancer Research (712 male; mean age at diagnosis, 62.6 years; s.d., 11.1 years); and (ii) 160 cases collected through the NCLLC (96 male; mean age at diagnosis, 65.3 years; s.d., 10.6 years) from patients attending six hematology units in the UK (Newcastle Royal Victoria Infirmary, Gateshead Queen Elizabeth Hospital, Birmingham Heartlands Hospital, Hull Royal Infirmary, Liverpool Royal University Hospital and The University of Wales College of Medicine Hospital). The proportion of incident and prevalent cases varied between clinical centers. All cases were UK residents and had self-reported European ancestry. Cases were genotyped using the Illumina Omni Express BeadChip according to the manufacturer's recommendations. For controls, we used publicly accessible Hap1.2M-Duo Custom array data generated by the WTCCC on 2,501 individuals from the UK Blood Service Control Group.
Details of the UK-CLL-1 study have been reported previously 3, 4 . Briefly, peripheral blood samples were collected from 517 individuals with CLL (364 male; mean age at diagnosis, 61.7 years; s.d., 9.9 years): 155 cases with at least one relative affected with CLL or a B-cell lymphoproliferative disorder (95 male; mean age at diagnosis, 58.9 years; s.d., 10.8 years) ascertained between 1997 and 2007 through the ICLLLC, which is an ongoing initiative to ascertain and collect CLL cases and families segregating CLL and B-cell lymphoproliferative disorder through clinical centers, and 362 cases (269 male; mean age at diagnosis, 62.9 years; s.d., 9.3 years) ascertained between 1999 and 2004 through Leukemia Research CLL-4, a randomized phase 3 trial 26 . Blood samples from the cases were collected at registration. All cases were British residents and had self-reported European ancestry. Genotyping of cases was performed using Illumina Human 317K arrays according to the manufacturer's protocols. For controls, we used publicly accessible data generated by the WTCCC on 2,698 individuals from the 1958 Birth cohort (58C, also known as the National Child Development Study) 27 .
Quality control of GWAS data sets. DNA samples with GenCall scores <0.25 at any locus were considered 'no calls' . A SNP was deemed to have failed if <95% of DNA samples generated a genotype at the locus. Cluster plots were manually inspected for all SNPs considered for replication. The same quality control metrics on the primary GWAS data were applied as in the previous UK-CLL-1 study 3 . We removed from the analysis individuals showing sex discrepancy (0 samples) and samples for whom <95% of SNPs were successfully genotyped (13 samples; Supplementary Fig. 2) . We computed identity-by-state (IBS) probabilities for all pairs (cases and controls) to search for duplicates and closely related individuals among samples (defined as IBS ≥ 0.80, thereby excluding first-degree relatives). For all related pairs, the sample with the highest call rate was retained, thereby eliminating 13 samples. To identify individuals who might have non-Western European ancestry, we merged our case and control data with phase II HapMap samples (60 western European (CEU), 60 Nigerian (YRI) and 90 Japanese (JPT) and Han Chinese (CHB)). For each pair of individuals, we calculated genome-wide IBS distances on markers shared between HapMap and our SNP panel and used these as dissimilarity measures on which to perform principal components analysis. We plotted the first two principal components for each individual and excluded from analyses nine samples showing marked separation from the CEU cluster (Supplementary Fig. 5 ). We filtered out SNPs with MAF <1% and call rate <95% in cases or controls. We also excluded SNPs showing departure from Hardy-Weinberg equilibrium at P < 10 −5 . For replication and validation analyses, call rates were >95% per 384-well plate for each SNP; cluster plots were visually examined by two researchers.
Replication series and genotyping. The UK replication series comprised 340 cases collected through the NCLLC and 463 cases collected through the Leicester Haematology Tissue Bank of consecutive cases presenting to the CLL clinic in Leicester. Controls comprised 2,780 healthy individuals ascertained through the National Study of Colorectal Cancer (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) 28 (n = 676, 225 male); the Genetic Lung Cancer Predisposition Study 29 (n = 693, 162 male); the Colorectal Adenoma Gene-Environment Interactions Study (n = 686, 382 male); the Study of the Genetic Epidemiology of Colorectal Cancer (n = 174, 88 male); and the Royal Marsden Hospitals National Health Service Trust family history DNA database (n = 551, 217 male). These controls were the spouses or unrelated friends of individuals with malignancies. None had a personal history of malignancy at the time of ascertainment. Both cases and controls were British residents and had self-reported European ancestry.
The Swedish replication series comprised 271 cases from the SCALE study 30 and 70 cases from the biobank at Uppsala University Hospital, Uppsala, Sweden (220 male; mean age at diagnosis, 62. Genotyping was performed using competitive allele-specific PCR KASPar chemistry (LGC Genomics Ltd). All primers and probes used are available on request. Samples with SNP call rates <90% were excluded from the analysis.
To ensure the quality of genotyping in all assays, at least two negative controls and 1-2% duplicates (showing concordance >99.99%) were genotyped.
Mutational status. IGHV gene mutation status was determined according to BIOMED-2 protocols as described previously 31 . Sequence analysis was conducted using Chromas software version 2.23 (Applied Biosystems) and the international ImMunoGeneTics information system database. In accordance with published criteria, we classified sequences with germline identity of ≥98% as being unmutated and those with identity of <98% as being mutated 32 .
Telomere length. The telomere length of genomic DNA extracted from mononuclear blood cells was determined using real-time PCR 33, 34 . The mean interassay coefficient of variation for relative telomere length was 4-8% (ref. 35 ). Telomere and single-copy gene values were calculated by 2 −∆Ct methodology.
Statistical and bioinformatic analyses. Main analyses were undertaken using R (v2.6), Stata v.10 (State College, Texas, USA) and PLINK (v1.06) 36 software. The association between each SNP and risk was assessed by the Cochran-Armitage trend test. The adequacy of the case-control matching and the possibility of differential genotyping of cases and controls were formally evaluated using quantile-quantile plots of P values derived from test statistics. The inflation factor, λ, was based on the 90% least significant SNPs 37 . ORs and associated 95% CIs were calculated by unconditional logistic regression. Meta-analysis was performed using the fixed-effects inverse-variance method based on β and the standard errors 38 . Cochran's Q statistics to test for heterogeneity and I 2 statistics to quantify the proportion of the total variation due to heterogeneity were calculated 39 . I 2 ≥ 75% is considered to be characteristic of large heterogeneity 39 , and in such cases, the random-effects model was applied.
Associations by sex, age and IGHV mutation status were examined by logistic regression in case-only analyses. Telomere length across genotypes was compared by the Kruskal-Wallis test. The combined effect of pairs of loci identified with risk was investigated by logistic regression modeling. Evidence for interactive effects between SNPs was assessed by a likelihood ratio test comparing the fit of the null model and a model including the interaction term; the difference in log-likelihood ratio statistics was assessed by χ 2 test. The sibling relative risk attributable to each SNP was calculated using the formula: where p is the population frequency of the minor allele, q = 1 − p, and r 1 and r 2 are the ORs for heterozygotes and rare homozygotes, respectively, relative to common homozygotes. Assuming an overall sibling relative risk (λ 0 ) of 8.5 for CLL 2 and a multiplicative interaction, the proportion of the familial risk attributable to SNP genotypes was calculated as log(λ * )/log(λ 0 ). Prediction of the untyped SNPs was carried out using IMPUTEv2 based on the 1000 Genomes phase 1 integrated variant set (b37) from March 2012. Imputed data were analyzed using SNPTEST v2 to account for uncertainties in SNP prediction. Association meta-analyses included only markers with info scores >0.4, Hardy-Weinberg equilibrium P > 10 −5 and missingness rate <0.05. Meta-analyses were carried out in R using the genotype probabilities from IMPUTEv2 where a SNP was not directly typed.
LD metrics were calculated in PLINK using 1000 Genomes data and plotted using SNAP. LD blocks were defined on the basis of HapMap recombination rate (cM/Mb) as defined using the Oxford recombination hotspots 40 and on the basis of the distribution of CIs defined by Gabriel et al. 41 .
To explore the epigenetic profile of association signals, we used chromatin state segmentation in LCL data generated by the ENCODE project 7 . The states were inferred from ENCODE histone modification data (histone H4 Lys20 methylation (H4K20me1), H3 Lys9 acetylation (H3K9ac), H3K4me3, H3K4me2, H3K4me1, H3K36me3, H3K27me3, H3K27ac and CCCTC-binding factor (CTCF)) binarized using a multivariate hidden Markov model. We used HaploReg 42 and RegulomeDB 43 to examine whether any of the SNPs or their proxies (i.e., r 2 > 0.8 in the 1000 Genomes EUR reference panel) annotate putative transcription factor binding or enhancer elements. We assessed sequence conservation using GERP. GERP scores (−12 to 6, with 6 being indicative of complete conservation) reflect the proportion of substitutions at that site that are rejected by selection compared with the observed substitutions expected under a neutral evolutionary model based on sequence alignment of 34 mammalian species 44 .
Relationship between SNP genotype and mRNA expression. To look for a relationship between SNP genotype and expression levels in lymphocytes, we used publicly available expression data generated on LCLs from the MuTHER resource using a combination of Illumina HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M chips. Data were examined using Genevar 45 .
